Home Tags Mirvetuximab soravtansine

Tag: Mirvetuximab soravtansine

Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

ASCO 2022: SORAYA Study Shows Consistent Safety Profile for Mirvetuximab Soravtansine...

Mirvetuximab soravtansine, previously know as IMGN853, shows a tumor reduction in 71.4% of patients and preliminary median overall survival of 13.8 months in high folate receptor...

ImmunoGen Submits Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer

Immunogen has submitted a Biologics License Application (BLA) under the accelerated approval pathway to the US Food and Drug Administration (FDA) for mirvetuximab soravtansine...

Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

The Phase 3 SOROYA trial demonstrated  promising response rates with mirvetuximab soravtansine, previously known as  IMGN853, in patients with platinum-resistant ovarian cancer and high folate receptor–alpha...

Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize...

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in 1993, have entered into an...

AACR 2020: A Next Generation of FRα-Targeting ADC Engineered to Maximize...

Preclinical data for ImmunoGen's next-generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression...

ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent...

Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853), in combination with bevacizumab (Avastin®;...

Confirmatory Study of Mirvetuximab Soravtansine in Ovarian Cancer on Track to...

In a statement earlier today, ImmunoGen confirmed that the U.S. Food and Drug Administration (FDA) has advised that a new single-arm study in platinum-resistant...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

FORWARD II Triplet Combination Demonstrates Encouraging Anti-tumor Activity

Safety and overall response data from the Phase Ib FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and bevacizumab (Avastin®; Genentech/Roche)...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer...

The full data and exploratory analyses from the Phase III FORWARD I study (NCT02631876) evaluating mirvetuximab soravtansine, also known as IMGN853, compared to chemotherapy...

ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine

Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...

X